RESUMEN
HLA typing was performed on 18 patients suffering from sarcoidosis and 30 patients suffering from diffuse interstitial pulmonary fibrosis. One hundred normal healthy people ethnically matched served as the controls. On statistical analysis, the corrected 'p' value of all the HLA antigens for both the patient groups was non significant. The results therefore suggest that there is no particular HLA antigen associated with sarcoidosis and diffuse interstitial pulmonary fibrosis.
Asunto(s)
Estudios de Casos y Controles , Etnicidad , Antígenos HLA/análisis , Antígenos HLA-A/análisis , Antígenos HLA-B/análisis , Antígenos HLA-C/análisis , Antígenos HLA-DR/análisis , Humanos , Enfermedades Pulmonares/inmunología , Fibrosis Pulmonar/inmunología , Sarcoidosis/inmunologíaRESUMEN
Twenty-five resident doctors were given 1 ml (20 micrograms) of recombinant hepatitis B vaccine intramuscularly in the deltoid region at 0, 1 and 6 months. Seroconversion rates at 1, 2, 3, 7 and 8 months were 8%, 48%, 64%, 96% and 100% respectively. Acceptability of the vaccine was 100%. The recombinant hepatitis B vaccine is safe and efficacious, with seroconversion rates comparable to the plasma derived vaccine, and has negligible side effects.